[ブログ記事の字数制限のため一覧を分割]
新型コロナウイルスのPDB公開構造一覧: その4(本記事); - その3; - その2; - その1
[参考: PDBjの新型コロナウイルスの構造情報]
# |
ID |
Title |
Release Date |
35 |
The crystal structure of 3CL MainPro of SARS-CoV-2 with C145S mutation (#24の6XKFの登録者共通) |
07/15/2020 |
|
34 |
SARS-CoV-2 HexaPro S One RBD up [Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes] |
07/15/2020 |
|
33 |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1 |
07/08/2020 |
|
32 |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022 |
07/08/2020 |
|
31 |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3 |
07/08/2020 |
|
30 |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022 |
07/08/2020 |
|
29 |
Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab |
07/08/2020 |
|
28 |
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab |
06/24/2020 |
|
27 |
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody |
06/24/2020 |
|
26 |
1.70 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 7j |
07/08/2020 |
|
25 |
Covalent complex of SARS-CoV-2 main protease with N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide [The Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19] |
07/08/2020 |
|
24 |
The crystal structure of 3CL MainPro of SARS-CoV-2 with oxidized Cys145 (Sulfenic acid cysteine) |
07/08/2020 |
|
23 |
THE 1.28A CRYSTAL STRUCTURE OF 3CL MAINPRO OF SARS-COV-2 WITH OXIDIZED C145 (sulfinic acid cysteine) |
07/08/2020 |
|
22 |
Room Temperature Structure of SARS-CoV-2 NSP10/NSP16 Methyltransferase in a Complex with SAM Determined by Fixed-Target Serial Crystallography |
07/08/2020 |
|
21 |
Room temperature X-ray crystallography reveals oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL Mpro: Insights for enzyme mechanism and drug design |
07/01/2020 |
|
20 |
Furin Cleaved Spike Protein of SARS-CoV-2 with One RBD Erect |
07/01/2020 |
|
19 |
Furin Cleaved Spike Protein of SARS-CoV-2 in Intermediate Conformation |
07/01/2020 |
|
18 |
S protein of SARS-CoV-2 in complex bound with 4A8 |
07/01/2020 |
|
17 |
Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing antibody, CV30 Fab |
07/01/2020 |
|
16 |
SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab |
07/01/2020 |
|
15 |
Crystal Structure of C-terminal Dimerization Domain of Nucleocapsid Phosphoprotein from SARS-CoV-2, crystal form II |
07/01/2020 |
|
14 |
Structure of the prefusion SARS-CoV-2 spike glycoprotein |
07/01/2020 |
|
13 |
SARS-CoV-2 S in complex with the C105 neutralizing antibody Fab fragment (state 1) |
07/01/2020 |
|
12 |
The 1.5 A Crystal Structure of the Co-factor Complex of NSP7 and the C-terminal Domain of NSP8 from SARS CoV-2 |
07/01/2020 |
|
11 |
The crystal structure of COVID-19 main protease in complex with GC376 |
06/24/2020 |
|
10 |
Structure of sybody MR17-K99Y in complex with the SARS-CoV-2 S Receptor-binding domain (RBD) [Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutratlization] |
06/24/2020 |
|
9 |
Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD) |
06/24/2020 |
|
8 |
Structure of sybody SR4 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) |
06/24/2020 |
|
7 |
Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with UAW243 |
06/24/2020 |
|
6 |
Nonstructural protein 10 (nsp10) from SARS CoV-2 |
06/24/2020 |
|
5 |
The 1.28A crystal structure of 3CL MainPro of SARS-CoV-2 with oxidized Cys145. |
06/24/2020 |
|
4 |
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab |
06/24/2020 |
|
3 |
Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies [Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.] |
06/24/2020 |
|
2 |
The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, at room temperature |
06/24/2020 |
|
1 |
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody. |
06/24/2020 |
2020-07-08までの更新履歴
2020-07-08 PDB 2020-07-08 公開エントリーを追加
#27と#28は2020-06-24公開であるが#29と同じbioRxiv 2020-06-13投稿掲載構造ということで再掲。
2020-07-01 PDB 2020-07-01 公開エントリーを追加
07-01公開エントリーについては、同一投稿または論文掲載分を1行にまとめた
(その中に07-01より以前に公開されたエントリーも再掲)
2020-06-28 PDB2020-06-24公開11エントリーを収録
コメント